BioWorld

April 22, 2002

MedImmune Enters Licensing Deals For Two Cancer Products

MedImmune Inc. agreed to spend an undisclosed amount of money expanding its cancer program through the licensure of two early stage technologies. (BioWorld Today) Read More

Telik, Sanwa Kagaku Extend Collaboration For Third Time

Calcium Prescribed To Ward Off Osteoporosis In Postmenopause Netted Good’ Cholesterol Bonus

Coastal City’s Misnamed Crabs Supporting Device, Drug Safety

Other News To Note

Appointments And Advancements

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...

Illustration of glucose in the blood stream

CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

BioWorld Science

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...